Chardan Capital Lowers uniQure (NASDAQ:QURE) Price Target to $16.00

uniQure (NASDAQ:QURE) had its target price decreased by Chardan Capital from $53.00 to $16.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Chardan Capital’s price objective points to a potential upside of 76.99% from the stock’s previous close.

QURE has been the topic of a number of other reports. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Tuesday, February 10th. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Wells Fargo & Company reduced their price target on shares of uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday, November 12th. Finally, TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, uniQure has a consensus rating of “Hold” and an average price target of $34.33.

uniQure Stock Up 0.1%

uniQure stock opened at $9.04 on Tuesday. The company has a market capitalization of $565.27 million, a PE ratio of -2.62 and a beta of 0.73. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50. The firm’s fifty day moving average is $22.54 and its 200 day moving average is $29.57. The company has a quick ratio of 7.12, a current ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, sell-side analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 12,378 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $295,339.08. Following the sale, the chief executive officer owned 639,076 shares in the company, valued at approximately $15,248,353.36. This trade represents a 1.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,598 shares of company stock valued at $1,248,588 over the last ninety days. Company insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several large investors have recently added to or reduced their stakes in QURE. Seven Fleet Capital Management LP purchased a new stake in shares of uniQure during the 4th quarter worth approximately $209,000. Virtus Investment Advisers LLC increased its position in uniQure by 91.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock worth $326,000 after purchasing an additional 6,520 shares during the last quarter. SummitTX Capital L.P. raised its stake in uniQure by 386.3% during the fourth quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock valued at $663,000 after purchasing an additional 22,010 shares in the last quarter. Suvretta Capital Management LLC bought a new position in uniQure during the fourth quarter valued at $29,116,000. Finally, Readystate Asset Management LP purchased a new position in shares of uniQure in the 4th quarter worth $8,652,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Q4 results beat expectations (EPS and revenue) and trading activity spiked after the release, which can support short‑term buying interest based on improved fundamentals and investor attention. uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume Following Strong Earnings
• Positive Sentiment: Technicals: analysts at Zacks note heavy recent selling has pushed QURE into oversold territory and consensus estimate revisions are moving higher — a technical + analyst alignment that could prompt a trend reversal or short‑covering bounce. uniQure (QURE) Loses 67.5% in 4 Weeks, Here’s Why a Trend Reversal May be Around the Corner
• Neutral Sentiment: Corporate/governance risk: uniQure disclosed it may fall under the Dutch “large company” regime next year, which would change shareholder control dynamics and could affect governance-related investor sentiment (longer‑term structural risk, not an immediate catalyst). uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments
• Negative Sentiment: Regulatory setback: the FDA has told uniQure to conduct another study of its Huntington’s gene therapy and senior FDA officials expressed doubt the current data demonstrate benefit. This materially weakens near‑term approval prospects and is the biggest immediate negative for the stock. FDA tells uniQure to conduct another study of Huntington’s gene therapy
• Negative Sentiment: Analyst downgrades and big price‑target cuts (Goldman, Wells Fargo, RBC, Mizuho and others) have followed the FDA news and earnings; several firms cut targets dramatically, lowering institutional support and amplifying selling pressure. uniQure (NASDAQ:QURE) Receives Equal Weight Rating from Wells Fargo & Company / price target changes
• Negative Sentiment: Legal/market risk: multiple law firms have filed or issued shareholder alerts about securities class actions tied to disclosures in late‑2025; active litigation and associated headlines increase legal risk and can deter investors. SHAREHOLDER ALERT: Berger Montague Reminds UniQure N.V. (QURE) Investors of Class Action Lawsuit Deadline

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.